PMID- 9840019
OWN - NLM
STAT- MEDLINE
DCOM- 19990202
LR  - 20131121
IS  - 0944-1174 (Print)
IS  - 0944-1174 (Linking)
VI  - 33 Suppl 10
DP  - 1998
TI  - Eradication therapies for Helicobacter pylori.
PG  - 53-6
AB  - Eradication therapies for Helicobacter pylori evolved from monotherapy, through 
      dual therapies and finally to bismuth-based triple therapies by the mid-1980s. 
      The advent of proton pump inhibitors (PPI) and clarithromycin added a new impetus 
      in the development of newer and often more effective regimens. Following large 
      numbers of therapeutic trials, two broad groups of therapies stand out which 
      consistently achieve over 90% eradication. Both are PPI-based. 
      PPI/amoxycillin/clarithromycin twice daily therapy is the simplest but perhaps 
      the most expensive. The 7-day quadruple (quad) therapy, consisting of a PPI and 
      bismuth/tetracycline/metronidazole, is rapidly emerging as the "all rounder" 
      therapy able not only to overcome metronidazole and clarithromycin resistance but 
      to also have a consistently high eradication rate of well over 90%. Extensive 
      clinical use of older and cut-down versions of combination therapies is resulting 
      in a rising population of treated patients who continue to be infected with H. 
      pylori, often resistant to further eradication attempts. Failure to recognise the 
      need to use regimens which achieve high first-time eradication success will lead 
      inexorably to an enlarging pool of patients with resistant strains and 
      "difficult-to-eradicate" H. pylori.
FAU - Borody, T J
AU  - Borody TJ
AD  - Centre for Digestive Diseases, Five Dock, NSW, Australia.
FAU - Shortis, N P
AU  - Shortis NP
FAU - Reyes, E
AU  - Reyes E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (Antacids)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Organometallic Compounds)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
RN  - HS813P8QPX (bismuth tripotassium dicitrate)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Amoxicillin/therapeutic use
MH  - Antacids/*therapeutic use
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Clarithromycin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Dyspepsia/drug therapy/microbiology
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Helicobacter Infections/diagnosis/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Omeprazole/therapeutic use
MH  - Organometallic Compounds/therapeutic use
MH  - Stomach Diseases/drug therapy/*microbiology
RF  - 10
EDAT- 1998/12/05 00:00
MHDA- 1998/12/05 00:01
CRDT- 1998/12/05 00:00
PHST- 1998/12/05 00:00 [pubmed]
PHST- 1998/12/05 00:01 [medline]
PHST- 1998/12/05 00:00 [entrez]
PST - ppublish
SO  - J Gastroenterol. 1998;33 Suppl 10:53-6.